Knee osteoarthritis (OA) represents a significant global health challenge, affecting over 365 million people worldwide and serving as a primary driver of healthcare costs and disability . For decades, the standard care pathway has followed a predictable trajectory: patient education and exercise, pain medication, corticosteroid injections, and ultimately, joint replacement surgery. Yet this traditional model leaves many patients in a “gray area”—individuals whose symptoms are not adequately managed by conservative approaches but who are not yet candidates for, or are unwilling to undergo, surgical intervention . APOS therapy, a novel biomechanical foot-worn device, has emerged as a compelling solution for this underserved population, offering a non-invasive, mechanism-driven approach that addresses the root causes of pain rather than merely masking symptoms.
Understanding the Mechanism: Beyond Simple Unloading
APOS (All Phase Of Stance) therapy operates on a sophisticated dual mechanism that distinguishes it from conventional orthotics or footwear. The system comprises a specialized shoe with two convex rubber pods, called “Pertupods,” affixed to the sole. These pods are individually calibrated by trained clinicians based on gait analysis, with their position, size, and convexity customized to address each patient’s unique biomechanical dysfunction .
The first mechanism provides immediate biomechanical unloading. By precisely shifting the location of the Pertupods, the device alters the foot’s center of pressure, redirecting ground reaction forces away from the painful joint compartment. This can reduce the knee’s varus (adduction) moment by approximately 17%, directly decreasing the mechanical stress on the arthritic area . This effect is substantially greater than that observed with traditional lateral wedge orthotics, which typically achieve only 5-6% reduction and have shown inconsistent clinical efficacy.
However, the more transformative aspect of APOS lies in its second mechanism: neuromuscular retraining. The convex design of the pods introduces controlled micro-instability during walking, narrowing the base of support and challenging the patient’s postural stability . This intentional perturbation forces the lower extremity muscles to fire differently, activating and strengthening the neuromuscular pathways responsible for stability and control. Over time, this “built-in exercise intervention” retrains the patient’s gait pattern, teaching the body to move in a more biomechanically efficient and less painful manner . Critically, this retraining effect persists even when the device is not being worn, offering the potential for long-term functional improvement beyond the immediate pain relief .
Clinical Evidence and Guideline Endorsement
The clinical efficacy of APOS therapy is supported by a growing body of evidence, including a landmark randomized controlled trial published in the Journal of the American Medical Association (JAMA) . This robust research has demonstrated significant and clinically meaningful outcomes. A 70% average reduction in knee pain has been reported, with 89% of patients eligible for total knee replacement avoiding surgery for up to six years . Furthermore, treatment has been associated with a 61% decrease in pain medication use and a substantial 85% reduction in opioid usage, highlighting its potential to combat the ongoing opioid crisis .
These clinical outcomes translate into tangible healthcare system benefits. A retrospective claims analysis of over 600 patients demonstrated that APOS treatment was associated with an 80% reduction in healthcare costs compared to standard care, attributed to lower rates of surgeries, fewer specialist visits, and reduced need for imaging and injections . Patients with knee pain reported significant pain decreases of 39% and 35% at three and six months post-treatment, respectively . This real-world evidence of both clinical effectiveness and cost-savings is a powerful driver for adoption .
The strength of the evidence has led to recognition in major clinical guidelines. The European Alliance of Associations for Rheumatology (EULAR) updated its recommendations to include APOS for the management of knee and hip osteoarthritis . Similarly, the UK’s National Institute for Health and Care Excellence (NICE) has issued guidance supporting the technology, validating its adoption for a clearly defined patient cohort . NICE endorsement is particularly critical for NHS adoption, providing the assurance required for commissioners and providers to integrate the technology into routine care pathways .
Positioning in the Care Pathway
APOS therapy is not intended to replace all conservative measures but rather to serve as a highly effective option for patients who have failed standard non-surgical treatments. The NICE guidance specifies its intended use for adults with knee OA who have not responded adequately to standard care . Professor Oliver Pearce, a consultant orthopedic surgeon, describes this as the “gray area”—patients for whom core treatments like exercise, weight loss, physiotherapy, and steroid injections have provided insufficient relief .
The practical implementation of APOS involves a structured, year-long program. Following an initial gait analysis and device calibration, patients are prescribed a home-based regimen, typically wearing the device for 30 to 60 minutes per day during daily activities . Regular follow-ups allow for recalibration as the patient’s gait improves, ensuring the therapy remains optimally effective. This home-based nature is a key advantage, empowering patients to actively participate in their rehabilitation while maintaining their normal routines.
APOS therapy represents a paradigm shift in knee osteoarthritis management, moving beyond symptomatic relief to address the underlying biomechanical drivers of pain and dysfunction. By combining targeted load redistribution with neuromuscular retraining, it offers a non-invasive, evidence-based solution that can dramatically reduce pain, improve function, and delay or eliminate the need for surgery. With robust clinical evidence, inclusion in major guidelines, and demonstrable cost-effectiveness, APOS is poised to become an integral part of the modern knee OA care pathway, offering new hope for the millions of patients currently trapped in the “gray area” between conservative care and joint replacement .